Nature Communications (Jun 2022)
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
- Amanda Heard,
- Jack H. Landmann,
- Ava R. Hansen,
- Alkmini Papadopolou,
- Yu-Sung Hsu,
- Mehmet Emrah Selli,
- John M. Warrington,
- John Lattin,
- Jufang Chang,
- Helen Ha,
- Martina Haug-Kroeper,
- Balraj Doray,
- Saar Gill,
- Marco Ruella,
- Katharina E. Hayer,
- Matthew D. Weitzman,
- Abby M. Green,
- Regina Fluhrer,
- Nathan Singh
Affiliations
- Amanda Heard
- Division of Oncology, Washington University School of Medicine
- Jack H. Landmann
- Division of Oncology, Washington University School of Medicine
- Ava R. Hansen
- Department of Pediatrics, Washington University School of Medicine
- Alkmini Papadopolou
- Biochemistry and Molecular Biology, Institute of Theoretical Medicine, Medical Faculty, University of Augsburg
- Yu-Sung Hsu
- Division of Oncology, Washington University School of Medicine
- Mehmet Emrah Selli
- Division of Oncology, Washington University School of Medicine
- John M. Warrington
- Division of Oncology, Washington University School of Medicine
- John Lattin
- Division of Oncology, Washington University School of Medicine
- Jufang Chang
- Division of Oncology, Washington University School of Medicine
- Helen Ha
- Division of Oncology, Washington University School of Medicine
- Martina Haug-Kroeper
- Biochemistry and Molecular Biology, Institute of Theoretical Medicine, Medical Faculty, University of Augsburg
- Balraj Doray
- Division of Hematology, Washington University School of Medicine
- Saar Gill
- Division of Hematology and Oncology, University of Pennsylvania School of Medicine
- Marco Ruella
- Division of Hematology and Oncology, University of Pennsylvania School of Medicine
- Katharina E. Hayer
- Department of Biomedical and Health Informatics, The Children’s Hospital of Philadelphia
- Matthew D. Weitzman
- Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia
- Abby M. Green
- Department of Pediatrics, Washington University School of Medicine
- Regina Fluhrer
- Biochemistry and Molecular Biology, Institute of Theoretical Medicine, Medical Faculty, University of Augsburg
- Nathan Singh
- Division of Oncology, Washington University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-31035-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
Loss of surface CD19 expression by leukemic cells leads to resistance and relapse to CD19-targeted CAR-T therapies. Here the authors show that loss of SPPL3 in malignant B cells results in hyperglycosylation of CD19.
